Maxim analyst Jason McCarthy upgraded Reviva Pharmaceuticals (RVPH) to Buy from Hold with a $7 price target
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals initiated with a Buy at Roth MKM
- Reviva Pharmaceuticals Strengthens Financial Position with Offering
- Reviva Pharmaceuticals 12M share Spot Secondary priced at $1.50
- Reviva Pharmaceuticals announces common stock, warrant offering, no amount given
- Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results